Efficacy and safety of colchicine for atrial fibrillation prevention: An updated meta-analysis of randomized controlled trials

Tian, Xu; Zhang, Nan; Korantzopoulos, Panagiotis; Bazoukis, George; Letsas, Konstantinos P.; Tse, Gary; Liu, Tong

doi:10.1016/j.ijcard.2024.132068

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Book1

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Colchicine for the prevention of atrial fibrillation: Why do some studies say ‘yes’, and others say ‘no’?

Attia,

Hiram

2024

International Journal of Cardiology

View full text Add to dashboard Cite

Colchicine for the prevention of atrial fibrillation: Why do some studies say ‘yes’, and others say ‘no’?

Attia,

Hiram

2024

International Journal of Cardiology

View full text Add to dashboard Cite

How does atrial fibrillation cause development of atrial thrombosis and subsequent thromboembolism?

J.B. Robinson,

K. Sharma,

Sharma

et al. 2024

Atrial Fibrillation - Current Management and Practice [Working Title]

View full text Add to dashboard Cite

Atrial fibrillation is the most common arrhythmia and carries a substantial risk for embolic stroke which can be significantly mitigated by anticoagulant therapy. In this chapter, we review the epidemiology of atrial fibrillation and the biologic antecedents leading to atrial fibrillation. We then comment on the interaction between atrial fibrillation and atrial cardiopathy. We will explore the question of whether atrial cardiopathy alone can produce embolic stroke. We hope the reader will then focus on the expanding surge of atrial fibrillation closely aligned with the increasing burden of embolic stroke. There are additional cardioembolic strokes that appear to occur in the presence of atrial cardiopathy without the onset of atrial fibrillation. Promising new markers are available for predicting atrial cardiopathy and hence guiding treatment for initiation of DOACs. This has the potential to prevent many embolic strokes before they occur. Another missed clinical opportunity is aggressively targeting diastolic dysfunction with ACE-I, AT2 blockers, and MRAs to prevent the development of advanced atrial cardiopathy and subsequent embolic stroke and atrial fibrillation.

show abstract

Efficacy and safety of colchicine for atrial fibrillation prevention: An updated meta-analysis of randomized controlled trials

Cited by 2 publications

References 42 publications

Colchicine for the prevention of atrial fibrillation: Why do some studies say ‘yes’, and others say ‘no’?

Colchicine for the prevention of atrial fibrillation: Why do some studies say ‘yes’, and others say ‘no’?

How does atrial fibrillation cause development of atrial thrombosis and subsequent thromboembolism?

Contact Info

Product

Resources

About